When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
The company plans to launch its first bladder cancer test in the second half of the year, and is in the early stages of validating a third test for prostate cancer.
Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients.
